我们使用全国人口数据库，对之前患有乳腺癌、结肠直肠癌或胃癌的患者，检查了蛋白尿与心力衰竭（HF）和其他心血管疾病（CVD）事件的风险关联。我们使用JMDC索赔数据库进行这项回顾性观察研究，分析了55,191名之前患有乳腺癌、结肠直肠癌或胃癌的患者。中位年龄为54岁（48-60岁），20,665名参与者（37.4％）为男性。使用碱性尿液试纸数据作为基线参考值，3,945名和1,521名参与者被分类为具有迹量和阳性蛋白尿。使用Cox比例风险模型，我们检查了蛋白尿与HF和其他CVD事件发生率的关系。在平均随访2.8±2.2年的期间内，记录了1,597宗HF、124宗心肌梗死、1,342宗心绞痛、719宗中风和361宗房颤事件。Kaplan-Meier曲线显示HF的累积发病率随着蛋白尿类别增加而增加（log-rank p <0.001）。经过多变量调整后，蛋白尿迹量和阳性蛋白尿HF的风险比分别为1.24（95％CI，1.04-1.47）和1.62（95％CI，1.30-2.02）。蛋白尿也与心绞痛和房颤的风险增加相关。蛋白尿与之前患有癌症的患者发展HF和其他CVD事件的风险增加相关。为预防癌症患者HF，需要建立蛋白尿和癌症患者的最佳管理策略。 © 2022作者。由S. Karger AG，巴塞尔出版。

We examined the association of proteinuria with the risk for heart failure (HF) and other cardiovascular disease (CVD) events in patients with prior history of breast, colorectal, or stomach cancer using a nationwide population-based database.We conducted this retrospective observation study using the JMDC Claims Database and analyzed 55,191 patients with prior history of breast, colorectal, or stomach cancer. The median age was 54 (48-60) years, and 20,665 participants (37.4%) were men. Using urine dipstick data at baseline, 3,945 and 1,521 participants were categorized as having trace and positive proteinuria, respectively. Using Cox proportional hazards models, we examined the relationship of proteinuria with the incidence of HF and other CVD events.Over a mean follow-up of 2.8 ± 2.2 years, 1,597 HF, 124 myocardial infarction, 1,342 angina pectoris, 719 stroke, and 361 atrial fibrillation events were recorded. Kaplan-Meier curves showed that the cumulative incidence for HF increased with proteinuria category (log-rank p < 0.001). After multivariable adjustment, hazard ratios of trace and positive proteinuria for HF were 1.24 (95% CI, 1.04-1.47) and 1.62 (95% CI, 1.30-2.02), respectively. The presence of proteinuria was also associated with a higher risk for angina pectoris and atrial fibrillation.Proteinuria was associated with a greater risk of developing HF and other CVD events in patients with prior history of cancer. The optimal management strategy for patients with proteinuria and cancer needs to be established for the prevention of HF in cancer patients.© 2022 The Author(s). Published by S. Karger AG, Basel.